Wegovy 0.25 (Semaglutide PFS) 0.25mg

Wegovy 0.25 (semaglutide) is a prescription injectable pen for chronic weight management. This 0.25mg strength pen-injector supports gradual dose escalation. Ideal for adults with obesity or weight-related conditions. Compact and pre-filled for convenient at-home use.

Strength

0.25mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Novo Nordisk

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Wegovy 0.25 (semaglutide) is used to support weight management in adults with obesity or overweight with weight-related conditions. It is designed for those who need additional help alongside diet and exercise. The 0.25mg strength is typically the starting dose for gradual adjustment. Commonly prescribed for long-term use to aid in achieving and maintaining weight loss goals.

Side Effects

Users may notice reduced appetite and increased feelings of fullness after starting Wegovy 0.25. Some report gradual weight loss as the body adapts to the medication. Digestive effects like mild nausea are possible during initial use. Effects vary by individual and may take several weeks to become noticeable.

Precautions & Warnings

Store Wegovy 0.25 refrigerated between 2–8°C and protect from light. Do not freeze or use if frozen. Keep pens dry and avoid direct sunlight. Dispose of used pens properly in a sharps container. Always check the pen before use for damage or discoloration. Consult a healthcare provider for proper disposal guidance.

Avoid Interactions

Wegovy 0.25 may interact with medications that affect blood sugar, such as insulin or sulfonylureas. Alcohol use may increase the risk of side effects like dizziness or nausea. Always inform your healthcare provider about all medications and supplements you are taking. Some oral medications may require spacing due to delayed gastric emptying.

References

Frequently Asked Questions

Wegovy 0.25 (semaglutide) is used for chronic weight management in adults with obesity or overweight with weight-related conditions.

Store Wegovy 0.25 refrigerated between 2–8°C and protect from light; do not freeze.

Availability may vary by region; consult a licensed pharmacy or healthcare provider for online purchase options.

Common effects may include mild nausea, digestive discomfort, or reduced appetite during initial use.

Wegovy 0.25 is a pre-filled pen designed for once-weekly subcutaneous injection.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.